His primary areas of investigation include Internal medicine, Gastroenterology, Immunology, Pathology and Liver biopsy. His work in Internal medicine is not limited to one particular discipline; it also encompasses Surgery. The Gastroenterology study combines topics in areas such as Nonalcoholic fatty liver disease and Steatohepatitis.
His Immunology research is multidisciplinary, relying on both Mutation and Cytotoxic T cell. His work on Biopsy as part of general Pathology research is frequently linked to Consensus development, thereby connecting diverse disciplines of science. His study in Steatosis is interdisciplinary in nature, drawing from both TM6SF2, Adiponutrin and Insulin resistance.
The scientist’s investigation covers issues in Internal medicine, Gastroenterology, Pathology, Immunology and Liver biopsy. Nonalcoholic fatty liver disease, Cirrhosis, Fibrosis, Liver disease and Fatty liver are among the areas of Internal medicine where the researcher is concentrating his efforts. David E. Kleiner focuses mostly in the field of Cirrhosis, narrowing it down to topics relating to Hepatitis B and, in certain cases, Hepatitis B virus.
His Gastroenterology research incorporates themes from Biopsy, Steatohepatitis, Liver injury and Hepatitis C. His Pathology research includes themes of Hepatocellular carcinoma, Cancer research, Nodular regenerative hyperplasia and Hepatitis. The concepts of his Liver biopsy study are interwoven with issues in Autoimmune hepatitis and Hepatology.
His main research concerns Internal medicine, Gastroenterology, Fibrosis, Nonalcoholic fatty liver disease and Cirrhosis. His work in Liver biopsy, Steatosis, Liver disease, Biopsy and Steatohepatitis are all subfields of Internal medicine research. Steatohepatitis is a primary field of his research addressed under Fatty liver.
David E. Kleiner studies Gastroenterology, focusing on Transient elastography in particular. His Fibrosis study which covers Hepatology that intersects with Hepatitis. His research integrates issues of Stage, Endocrinology, Metabolic syndrome and Chronic liver disease in his study of Nonalcoholic fatty liver disease.
David E. Kleiner spends much of his time researching Internal medicine, Gastroenterology, Steatosis, Nonalcoholic fatty liver disease and Fibrosis. His study in Internal medicine focuses on Steatohepatitis, Cirrhosis, Fatty liver, Liver injury and Liver disease. His Fatty liver study incorporates themes from Clinical endpoint, Randomized controlled trial, Intention-to-treat analysis and Comorbidity.
In his study, which falls under the umbrella issue of Liver disease, Lung is strongly linked to Variceal bleeding. The various areas that David E. Kleiner examines in his Gastroenterology study include Interquartile range, Biopsy, Liver biopsy, Confidence interval and Prospective cohort study. His Fibrosis study integrates concerns from other disciplines, such as Clinical trial, Disease and MEDLINE.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
David E. Kleiner;Elizabeth M. Brunt;Mark Van Natta;Cynthia Behling.
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Arun J. Sanyal;Naga Chalasani;Kris V. Kowdley;Arthur McCullough.
The New England Journal of Medicine (2010)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A Neuschwander-Tetri;Rohit Loomba;Arun J Sanyal;Joel E Lavine.
The Lancet (2015)
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Paul Angulo;David E. Kleiner;Sanne Dam-Larsen;Leon A. Adams.
Randomized Controlled Trial Testing the Effects of Weight Loss on Nonalcoholic Steatohepatitis
Kittichai Promrat;Kittichai Promrat;David E. Kleiner;Heather M. Niemeier;Heather M. Niemeier;Elizabeth Jackvony.
Quantitative zymography: detection of picogram quantities of gelatinases.
D.E. Kleiner;W.G. Stetlerstevenson.
Analytical Biochemistry (1994)
Matrix metalloproteinases and metastasis.
David E. Kleiner;William G. Stetler-Stevenson.
Cancer Chemotherapy and Pharmacology (1999)
Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents: The TONIC Randomized Controlled Trial
Joel E. Lavine;Jeffrey B. Schwimmer;Mark L. Van Natta;Jean P. Molleston;Jean P. Molleston.
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.
Kittichai Promrat;Glen Lutchman;Gabriel I. Uwaifo;Renee J. Freedman.
Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score and the Histopathologic Diagnosis in NAFLD: Distinct Clinicopathologic Meanings
Elizabeth M. Brunt;David E. Kleiner;Laura A. Wilson;Patricia Belt.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: